alanine has been researched along with Kidney Failure, Chronic in 40 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In hepatocytes isolated from uremic and control rats, we investigated: (1) the influence of uremia on gluconeogenesis and ureagenesis during incubations with alanine; (2) the kinetics of alanine plasma-membrane transport; (3) the relationships between intracellular alanine concentrations and its metabolism." | 7.72 | Effect of chronic renal failure with metabolic acidosis on alanine metabolism in isolated liver cells. ( Cano, N; El-Mir, MY; Leverve, XM; Meijer, AJ; Novaretti, R; Reynier, JP; Sturm, JM, 2004) |
| "In hepatocytes isolated from uremic and control rats, we investigated: (1) the influence of uremia on gluconeogenesis and ureagenesis during incubations with alanine; (2) the kinetics of alanine plasma-membrane transport; (3) the relationships between intracellular alanine concentrations and its metabolism." | 3.72 | Effect of chronic renal failure with metabolic acidosis on alanine metabolism in isolated liver cells. ( Cano, N; El-Mir, MY; Leverve, XM; Meijer, AJ; Novaretti, R; Reynier, JP; Sturm, JM, 2004) |
| " Other factors, including congestive heart failure, growth hormone deficiency, and hypoalaninemia might have contributed to the development of hypoglycemia in this patient." | 3.66 | Sulfonamide-induced hypoglycemia in chronic renal failure. ( Arem, R; Field, JB; Garber, AJ, 1983) |
| "Mucormycosis is an uncommon but serious infection that complicates the course of severe COVID-19." | 2.72 | Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. ( Agarwal, R; Bhalla, A; Chakrabarti, A; Garg, D; Kaur, H; Muthu, V; Puri, GD; Ramachandran, R; Sehgal, IS, 2021) |
| "Beta-hydrogen enrichment was approximately 80-100% of alpha-hydrogen enrichment." | 2.71 | Quantifying rates of protein synthesis in humans by use of 2H2O: application to patients with end-stage renal disease. ( Alexander, JC; Brunengraber, H; Chandramouli, V; Fatica, R; Landau, BR; Previs, SF, 2004) |
| "Insulin resistance plays a part in diabetic nephropathy (DN)." | 2.48 | Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. ( Chen, H; Chen, J; Hu, H; Mohan, V; Tang, Y; Venkatesan, R; Wang, J; Zhang, H; Zhu, S, 2012) |
| "The novel coronavirus disease 2019 (COVID-19) has led to a global pandemic since its emergence from Wuhan, China, in December of 2019." | 1.72 | Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD. ( Blanco, R; Haider, N; Patel, RH; Pella, PM, 2022) |
| "Hydroxychloroquine (HCQ) was used by 78." | 1.56 | Early impact of COVID-19 on transplant center practices and policies in the United States. ( Avery, RK; Boyarsky, BJ; Durand, CM; Garonzik-Wang, JM; Getsin, SN; Jackson, KR; Kernodle, AB; Massie, AB; Po-Yu Chiang, T; Segev, DL; Van Pilsum Rasmussen, SE; Werbel, WA, 2020) |
| " After comparing the pharmacokinetic behavior of panipenem in patients with ESRD and that of a surrogate marker of efficacy, we recommend that these patients be treated with 500 mg/500 mg of panipenem/betamipron once daily, which gives a similar clinical result in a patient with normal renal function." | 1.33 | Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. ( Hishida, A; Kanamaru, M; Nagashima, S; Ohashi, N; Tajima, N; Togawa, A; Uematsu, T, 2005) |
| "A total of 445 patients with type 2 diabetes who were enrolled in the Berlin Diabetes Mellitus Study and in whom we determined albuminuria and the presence of ESRF and retinopathy were genotyped for the PPAR-gamma2 Pro12Ala polymorphism." | 1.31 | Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. ( Brand, E; Herrmann, SM; Ringel, J; Staessen, JA; Wang, JG, 2002) |
| "The origin of this hypoglycemia is not clear but is probably multifactorial." | 1.26 | [Spontaneous hypoglycemia and chronic kidney insufficiency]. ( Caron, C; Langlois, M; Nawar, T; Robert, G, 1978) |
| "In 13 patients with chronic renal failure (creatinine = 10." | 1.26 | Abnormal carbohydrate metabolism in chronic renal failure. The potential role of accelerated glucose production, increased gluconeogenesis, and impaired glucose disposal. ( Garber, AJ; Rubenfeld, S, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (30.00) | 18.7374 |
| 1990's | 7 (17.50) | 18.2507 |
| 2000's | 6 (15.00) | 29.6817 |
| 2010's | 5 (12.50) | 24.3611 |
| 2020's | 10 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, RH | 1 |
| Pella, PM | 1 |
| Haider, N | 1 |
| Blanco, R | 1 |
| Haddad, I | 1 |
| Agarwal, P | 1 |
| Hassanein, M | 1 |
| Boyarsky, BJ | 1 |
| Po-Yu Chiang, T | 1 |
| Werbel, WA | 1 |
| Durand, CM | 1 |
| Avery, RK | 1 |
| Getsin, SN | 1 |
| Jackson, KR | 1 |
| Kernodle, AB | 1 |
| Van Pilsum Rasmussen, SE | 1 |
| Massie, AB | 1 |
| Segev, DL | 1 |
| Garonzik-Wang, JM | 1 |
| Hsu, JJ | 1 |
| Gaynor, P | 1 |
| Kamath, M | 1 |
| Fan, A | 1 |
| Al-Saffar, F | 1 |
| Cruz, D | 1 |
| Nsair, A | 1 |
| Adamsick, ML | 1 |
| Gandhi, RG | 1 |
| Bidell, MR | 1 |
| Elshaboury, RH | 1 |
| Bhattacharyya, RP | 1 |
| Kim, AY | 1 |
| Nigwekar, S | 1 |
| Rhee, EP | 1 |
| Sise, ME | 1 |
| Stanimirova, I | 1 |
| Banasik, M | 1 |
| Ząbek, A | 1 |
| Dawiskiba, T | 1 |
| Kościelska-Kasprzak, K | 1 |
| Wojtowicz, W | 1 |
| Krajewska, M | 1 |
| Janczak, D | 1 |
| Młynarz, P | 1 |
| Davis, MR | 1 |
| Pham, CU | 1 |
| Cies, JJ | 1 |
| Sörgel, F | 1 |
| Malin, JJ | 1 |
| Hagmann, H | 1 |
| Kinzig, M | 1 |
| Bilal, M | 1 |
| Eichenauer, DA | 1 |
| Scherf-Clavel, O | 1 |
| Simonis, A | 1 |
| El Tabei, L | 1 |
| Fuhr, U | 1 |
| Rybniker, J | 1 |
| Bruchfeld, A | 1 |
| Garg, D | 1 |
| Muthu, V | 1 |
| Sehgal, IS | 1 |
| Ramachandran, R | 1 |
| Kaur, H | 1 |
| Bhalla, A | 1 |
| Puri, GD | 1 |
| Chakrabarti, A | 1 |
| Agarwal, R | 1 |
| Tartaglia, A | 1 |
| Ferrara, SM | 1 |
| Sica, S | 1 |
| Santantonio, T | 1 |
| Ando, I | 2 |
| Takeuchi, K | 2 |
| Oguma, S | 2 |
| Sato, H | 2 |
| Sekino, H | 2 |
| Imai, Y | 2 |
| Fujiwara, M | 2 |
| Rurali, E | 1 |
| Noris, M | 1 |
| Chianca, A | 1 |
| Donadelli, R | 1 |
| Banterla, F | 1 |
| Galbusera, M | 1 |
| Gherardi, G | 1 |
| Gastoldi, S | 1 |
| Parvanova, A | 1 |
| Iliev, I | 1 |
| Bossi, A | 1 |
| Haefliger, C | 1 |
| Trevisan, R | 1 |
| Remuzzi, G | 1 |
| Ruggenenti, P | 1 |
| Sato, K | 1 |
| Zhang, H | 1 |
| Zhu, S | 1 |
| Chen, J | 1 |
| Tang, Y | 1 |
| Hu, H | 1 |
| Mohan, V | 1 |
| Venkatesan, R | 1 |
| Wang, J | 1 |
| Chen, H | 1 |
| Herrmann, SM | 1 |
| Ringel, J | 1 |
| Wang, JG | 1 |
| Staessen, JA | 1 |
| Brand, E | 1 |
| Previs, SF | 1 |
| Fatica, R | 1 |
| Chandramouli, V | 1 |
| Alexander, JC | 1 |
| Brunengraber, H | 1 |
| Landau, BR | 1 |
| Cano, N | 1 |
| Sturm, JM | 1 |
| Meijer, AJ | 1 |
| El-Mir, MY | 1 |
| Novaretti, R | 1 |
| Reynier, JP | 1 |
| Leverve, XM | 1 |
| Raj, DS | 1 |
| Welbourne, T | 1 |
| Dominic, EA | 1 |
| Waters, D | 1 |
| Wolfe, R | 1 |
| Ferrando, A | 1 |
| Ohashi, N | 1 |
| Uematsu, T | 1 |
| Nagashima, S | 1 |
| Kanamaru, M | 1 |
| Tajima, N | 1 |
| Togawa, A | 1 |
| Hishida, A | 1 |
| Arem, R | 1 |
| Garber, AJ | 4 |
| Field, JB | 1 |
| Heaton, A | 1 |
| Johnston, DG | 1 |
| Burrin, JM | 1 |
| Orskov, H | 1 |
| Ward, MK | 1 |
| Alberti, KG | 1 |
| Kerr, DN | 1 |
| Dumbauld, SL | 1 |
| Rutsky, EA | 1 |
| McDaniel, HG | 1 |
| Jiang, J | 1 |
| Calzavara, P | 1 |
| Marangella, M | 1 |
| Petrarulo, M | 1 |
| Ballanti, P | 1 |
| Bonucci, E | 1 |
| Calconi, G | 1 |
| Maresca, MC | 1 |
| da Porto, A | 1 |
| Vianello, A | 1 |
| Guth, HJ | 1 |
| Wiersbitzky, M | 1 |
| Ziesche, M | 1 |
| Rose, HJ | 1 |
| Kraatz, G | 1 |
| Chen, D | 1 |
| Crimmins, DL | 1 |
| Hsu, FF | 1 |
| Lindberg, FP | 1 |
| Scott, MG | 1 |
| Lazzara, S | 1 |
| Pergolizzi, FP | 1 |
| Melita, G | 1 |
| Cavaleri, A | 1 |
| Tigano, D | 1 |
| Riso, F | 1 |
| Furby, A | 1 |
| Mourtada, R | 1 |
| Charasse, C | 1 |
| Rivalan, J | 1 |
| Messner, M | 1 |
| Leroy, JP | 1 |
| Rubenfeld, S | 2 |
| Langlois, M | 1 |
| Robert, G | 1 |
| Nawar, T | 1 |
| Caron, C | 1 |
| Ruderman, NB | 1 |
| Macpherson, NA | 1 |
| Moscarello, MA | 1 |
| Goldberg, DM | 1 |
| Ish-Shalom, N | 1 |
| Arbus, GS | 1 |
| Parrish, A | 1 |
| Zikira, M | 1 |
| Tomacelli, C | 1 |
| Kenney, R | 1 |
| Davis, TA | 1 |
| Karl, IE | 1 |
| Tegtmeyer, ED | 1 |
| Osborne, DF | 1 |
| Klahr, S | 1 |
| Harter, HR | 1 |
| Deferrari, G | 1 |
| Garibotto, G | 1 |
| Robaudo, C | 1 |
| Canepa, A | 1 |
| Bagnasco, S | 1 |
| Tizianello, A | 1 |
| Dotchev, D | 1 |
| Hungerland, H | 1 |
| Liappis, N | 1 |
| Oyanagi, K | 1 |
| Bier, DM | 1 |
| Cryer, PE | 1 |
| Pagliara, AS | 1 |
| Czerniak, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer[NCT04859244] | Phase 1 | 1 participants (Actual) | Interventional | 2021-01-01 | Completed | ||
| A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)[NCT00235014] | Phase 4 | 1,204 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| Evaluation of p21 Induction and Molecular Pathways Related to Short-term Fasting Response[NCT04259879] | 20 participants (Actual) | Interventional | 2016-04-07 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for alanine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Alanine; Antiviral Agents; Cause of Death; Comorbidity | 2020 |
The COVID-19 pandemic: consequences for nephrology.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Tre | 2021 |
Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; Diabetes Complications; Glucocorticoid | 2021 |
Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies.
Topics: Alanine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Genetic Predisposition to Diseas | 2012 |
Muscle amino acid metabolism and gluconeogenesis.
Topics: Adaptation, Physiological; Alanine; Amino Acids; Aminoacylation; Animals; Fasting; Forearm; Gluconeo | 1975 |
1 trial available for alanine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Quantifying rates of protein synthesis in humans by use of 2H2O: application to patients with end-stage renal disease.
Topics: Adult; Aged; Alanine; Body Water; Deuterium Oxide; Female; Humans; Hydrogen; Kidney Failure, Chronic | 2004 |
34 other studies available for alanine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Kidne | 2022 |
Remdesivir use in COVID-19 patients with end-stage kidney disease on intermittent hemodialysis: An absolute contraindication?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Contraindications; COVID-19 Drug Treatment; Huma | 2022 |
Early impact of COVID-19 on transplant center practices and policies in the United States.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Betacoronavirus; Clinical Labor | 2020 |
COVID-19 in a high-risk dual heart and kidney transplant recipient.
Topics: Adenosine Monophosphate; Adult; Alanine; Betacoronavirus; Cardiomyopathy, Dilated; Coronavirus Infec | 2020 |
Serum metabolomics approach to monitor the changes in metabolite profiles following renal transplantation.
Topics: Alanine; Biomarkers; Health Status; Hippurates; Humans; Kidney Failure, Chronic; Kidney Transplantat | 2020 |
Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Furans; Humans; Kidney Failure, Chronic; Pyrroles; Rena | 2021 |
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; | 2021 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, | 2017 |
¹H NMR spectroscopic quantification of plasma metabolites in dialysate during hemodialysis.
Topics: Aged; Alanine; Biomarkers; Blood Chemical Analysis; Creatinine; Dialysis Solutions; Female; Humans; | 2013 |
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Alanine; Angiotensin-Converting Enzyme Inhibitors; Biomarkers | 2013 |
Metabolic responses during hemodialysis determined by quantitative (1)H NMR spectroscopy.
Topics: Aged; Alanine; Creatinine; Female; Humans; Kidney Failure, Chronic; Lactic Acid; Magnetic Resonance | 2015 |
Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study.
Topics: Alanine; Amino Acid Substitution; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2002 |
Effect of chronic renal failure with metabolic acidosis on alanine metabolism in isolated liver cells.
Topics: Acidosis; Alanine; Animals; Cells, Cultured; Gluconeogenesis; Hepatocytes; Kidney Failure, Chronic; | 2004 |
Glutamine kinetics and protein turnover in end-stage renal disease.
Topics: Adult; Alanine; Arteries; Diabetes Mellitus, Type 2; Female; Glutamic Acid; Humans; Kidney Failure, | 2005 |
Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease.
Topics: Adult; Aged; Alanine; Anti-Bacterial Agents; Area Under Curve; Dose-Response Relationship, Drug; Fem | 2005 |
Sulfonamide-induced hypoglycemia in chronic renal failure.
Topics: Aged; Alanine; Female; Glucagon; Glucose; Glucose Tolerance Test; Growth Hormone; Heart Failure; Hum | 1983 |
Carbohydrate and lipid metabolism during continuous ambulatory peritoneal dialysis (CAPD): the effect of a single dialysis cycle.
Topics: Adult; Aged; Alanine; Blood Glucose; Carbohydrates; Fatty Acids, Nonesterified; Female; Glucagon; Gl | 1983 |
Carbohydrate metabolism during fasting in chronic hemodialysis patients.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Alanine; Blood Glucose; Fasting; Fatty Acids, Nonesteri | 1983 |
[The turnover of three amino acids in the plasma of chronic renal failure patients].
Topics: Adult; Aged; Alanine; Amino Acids; Humans; Kidney Failure, Chronic; Leucine; Middle Aged; Phenylalan | 1993 |
Long-term survival on renal replacement therapy for primary hyperoxaluria type I.
Topics: Adult; Alanine; Glycolates; Humans; Hyperoxaluria, Primary; Kidney Failure, Chronic; Kidney Transpla | 1993 |
Which amino-acids do serum and hemofiltrate of critically ill patients with acute renal failure contain?
Topics: Alanine; Amino Acids; Asparagine; Citrulline; Cystathionine; Ethanolamines; Extracorporeal Circulati | 1997 |
Hemoglobin Raleigh as the cause of a falsely increased hemoglobin A1C in an automated ion-exchange HPLC method.
Topics: Aged; Alanine; Amino Acid Substitution; Autoanalysis; Chromatography, High Pressure Liquid; Chromato | 1998 |
[Alpha-glucosidase and alanine-amino-peptidase in the early diagnosis of renal failure in obstructive jaundice].
Topics: Adult; Aged; Alanine; alpha-Glucosidases; Aminopeptidases; Cholestasis; Diagnosis, Differential; Fem | 1997 |
[Polyradiculoneuropathy in an adult with primitive hyperoxaluria].
Topics: Adult; Alanine; Biopsy; Disease Progression; Humans; Hyperoxaluria, Primary; Kidney Failure, Chronic | 2000 |
Impact of hemodialysis on the abnormal glucose and alanine kinetics of chronic azotemia.
Topics: Adult; Alanine; Blood Glucose; Female; Glucose; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 1979 |
[Spontaneous hypoglycemia and chronic kidney insufficiency].
Topics: Adult; Alanine; Female; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemia; Insulin; Kidney Fail | 1978 |
Abnormal carbohydrate metabolism in chronic renal failure. The potential role of accelerated glucose production, increased gluconeogenesis, and impaired glucose disposal.
Topics: Adult; Aged; Alanine; Female; Gluconeogenesis; Glucose; Humans; Kidney Failure, Chronic; Kinetics; M | 1978 |
Aminoaciduria as a marker of acute renal transplant rejection--a patient study.
Topics: Adolescent; Alanine; Amino Acids; Child; Child, Preschool; Creatinine; Female; Glycine; Graft Reject | 1991 |
Carbohydrate utilization in exercising muscle in subtotally nephrectomized rabbits.
Topics: Alanine; Animals; Carbohydrate Metabolism; Glutamine; Glycogen; Ketoglutaric Acids; Kidney; Kidney F | 1990 |
Muscle protein turnover: effects of exercise training and renal insufficiency.
Topics: Alanine; Animals; Body Weight; Carbon Radioisotopes; Female; Insulin; Kidney Failure, Chronic; Muscl | 1985 |
Leg metabolism of amino acids and ammonia in patients with chronic renal failure.
Topics: Adult; Alanine; Amino Acids; Ammonia; Arteries; Chromatography, Ion Exchange; Female; Femoral Vein; | 1985 |
[Hyperiminoaciduria and disaminoaciduria in endemic (Balkan-)nephropathy (author's transl)].
Topics: Adult; Aged; Alanine; Amino Acids; Chromatography, Thin Layer; Chronic Disease; Creatinine; Female; | 1974 |
Hypoglycemia in compensated chronic renal insufficiency. Substrate limitation of gluconeogenesis.
Topics: Alanine; Carbon Radioisotopes; Diabetic Nephropathies; Female; Fluorometry; Glucagon; Gluconeogenesi | 1974 |
N-substituted amino acids in serum of patients with chronic renal insufficiency.
Topics: Alanine; Amino Acids; Aspartic Acid; Cystine; Glutamates; Glycine; Humans; Kidney Failure, Chronic; | 1970 |